University of Virginia, Charlottesville, VA
Keio University, Tokyo, Japan
Naoko Ronquest, PhD, is an Executive Director, US HTA Strategy and Early Modeling in the Health Economics Group at RTI-HS. She has more than 12 years of experience in health economics and outcomes research. In addition to having a solid methodological background in developing pharmacoeconomic models across a range of therapeutic areas, she has comprehensive experience in conducting an array of health economics and outcomes research (HEOR) initiatives and applying research outcomes in supporting market access of new products. Specifically, she has extensive experience in developing evidence generation strategies and utilizing HEOR evidence to support health technology assessments including Institute for Clinical and Economic Review (ICER) evaluations and reimbursement submissions in a variety of global markets. In addition, she has routinely collaborated with large interdisciplinary teams of clinicians, epidemiologists, statisticians, economists, and commercial leaders to lead the design of health economic models and presented research findings in various professional meetings. Dr. Ronquest has in-depth experience incorporating HEOR considerations into clinical trials, designing trial data analyses, and synthesizing clinical and economic evidence to demonstrate the value of pharmaceutical products.
Dr. Ronquest has published numerous articles in peer-reviewed journals and has research experience in a variety of therapeutic areas including addiction, ophthalmology, pain, cancer, diabetes, schizophrenia, lupus, HIV, hepatitis, sexual dysfunction, acute coronary syndrome, heart failure, atopic dermatitis, rheumatoid arthritis, and joint arthroplasty. Prior to joining RTI- HS, Dr. Ronquest was a Director of Global HEOR at Indivior Pharmaceuticals and was responsible for developing and implementing global HEOR strategy for launching a new therapy for opioid use disorder.